On March 8, 2022 Blueprint Medicines Corporation (NASDAQ: BPMC) reported plans to present new clinical and preclinical data for multiple programs across its precision therapy portfolio at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 in New Orleans, April 8 to 13 (Press release, Blueprint Medicines, MAR 8, 2022, View Source [SID1234609727]). The presentations highlight Blueprint Medicines’ next wave of therapeutic candidates in its growing pipeline. These investigational treatments could bring the promise of precision medicine to broad patient populations with genomically defined cancers, including lung, ovarian and breast cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"At AACR (Free AACR Whitepaper), we plan to unveil a constellation of data highlighting our scientific leadership in precision therapy, and reflecting our commitment to rapidly translate research into transformative medicines for patients," said Fouad Namouni, M.D., President of Research and Development at Blueprint Medicines. "With multiple drug candidates entering clinical trials, our AACR (Free AACR Whitepaper) presentations feature initial results from the Phase 1/2 SYMPHONY study of BLU-945 in EGFR-driven non-small cell lung cancer, as well as data reinforcing our programs’ differentiated preclinical profiles and significant potential to advance patient care."

The accepted abstracts are listed below and available on the AACR (Free AACR Whitepaper) conference website: View Source

Clinical Trial and Late-Breaking Poster Presentations

Presentation Title: Emerging evidence of activity of BLU-945 in patients with advanced EGFR-mutant NSCLC utilizing circulating tumor DNA (ctDNA) in the phase 1/2 SYMPHONY study
Session Title: Phase I Clinical Trials 2
Session Date & Time: Tuesday, April 12, 2022 from 9:00 a.m. – 12:30 p.m. CT (10:00 a.m. – 1:30 p.m. ET)
Abstract Number: CT184
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 33

Presentation Title: Efficacy of a highly potent and selective KIT V654A inhibitor for treatment of imatinib resistant GIST
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 2
Session Date & Time: Wednesday, April 13, 2022 from 9:00 a.m. – 12:30 p.m. CT (10:00 a.m. – 1:30 p.m. ET)
Abstract Number: LB205
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 16

Poster Presentations

Presentation Title: LNG-451,* a potent inhibitor of EGFR exon 20 insertion mutations with high CNS exposure
Session Title: Epigenetic Targets
Session Date & Time: Tuesday, April 12, 2022 from 1:30 p.m. – 5:00 p.m. CT (2:30 p.m. – 6:00 p.m. ET)
Abstract Number: 3261
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 23

Presentation Title: LNG-451* is a potent, CNS-penetrant, wild-type EGFR sparing inhibitor of EGFR exon 20 insertion mutations
Session Title: Tyrosine Kinase and Phosphatase Inhibitors
Session Date & Time: Tuesday, April 12, 2022 from 1:30 p.m. – 5:00 p.m. CT (2:30 p.m. – 6:00 p.m. ET)
Abstract Number: 3332
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 26

Presentation Title: BLU-222, an investigational, potent, and selective CDK2 inhibitor, demonstrated robust antitumor activity in CCNE1-amplified ovarian cancer models
Session Title: Cell Cycle Control and Cell Cycle Regulators as Therapeutic Targets
Session Date & Time: Tuesday, April 12, 2022 from 9:00 a.m. – 12:30 p.m. CT (10:00 a.m. – 1:30 p.m. ET)
Abstract Number: 2306
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 5

Presentation Title: Antitumor activity of BLU-945 and BLU-701 as single agents and in combination in EGFR L858R-driven models of NSCLC
Session Title: Tyrosine Kinase and Phosphatase Inhibitors
Session Date & Time: Tuesday, April 12, 2022 from 1:30 p.m. – 5:00 p.m. CT (2:30 p.m. – 6:00 p.m. ET)
Abstract Number: 3328
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 26

* LNG-451 is now known as BLU-451.

Investor Conference Call Information

Blueprint Medicines will host a live webcast on Friday, April 8, 2022 beginning at 2:00 p.m. ET to discuss the data reported at AACR (Free AACR Whitepaper). On the day of the webcast, poster presentations will be made available on the AACR (Free AACR Whitepaper) conference website at 1:00 p.m. ET. To access the live call, please dial 844-200-6205 (domestic) or 929-526-1599 (international), and refer to conference ID 084402. A webcast of the conference call will be available in the Investors & Media section of Blueprint Medicines’ website at View Source The archived webcast will be available on Blueprint Medicines’ website approximately two hours after the conference call and will be available for 30 days following the call.